Authors
Latest:
Poll: Most anticipated emerging therapies in neovascular AMD and DMEA panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?
Latest:
Pearls for maintaining quality, safety in retina clinics amid a pandemicTo maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.
Latest:
Case 2: Management of Progressive Geographic Atrophy in an 84-Year-Old ManFerhina S. Ali, MD, MPH, discusses the management of progressive geographic atrophy in an 84-year-old man, focusing on the significance of patient education in optimizing treatment outcomes and adherence.
Latest:
Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the USThis agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.
Latest:
Setting a New Standard in Automated Tracked PerimetryInnovative new features build on the benefits of the iCare COMPASS Automated Perimeter
Latest:
OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trialsFerhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.
Latest:
A case of a 79-year-old pseudophakic patient with AMD and rapidly progressing GAThe final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.
Latest:
New guidelines boost choriocapillaris imaging in AMD with SS-OCTACompensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
Latest:
Ophthalmologist shares his story on Holocaust Remembrance DayJohn H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.
Latest:
Searching for durable therapies for diabetic macular edema amid the pandemicPatients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.
Latest:
Prevent Blindness announces leadership promotionsAs part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.
Latest:
Optimizing Care For Patients With Retinal DisordersKey takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Latest:
Exploring cryopreserved amniotic membrane following intravitreal injectionCAM encourages corneal healing in patients with ocular surface disease.
Latest:
Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitisLong-term sustained-release therapy pays off in management of chronic, vision-threatening disease.
Latest:
Impact of Durable Therapies on Patients and Clinics and Monitoring StrategiesPanelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.
Latest:
DR/DME: Ongoing Clinical Trials and New Diagnostic ToolsCarolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).
Latest:
New guidelines boost choriocapillaris imaging in AMD with SS-OCTACompensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.
Latest:
Broadening the benefits of iCare EIDON retinal imaging with the new Ultra-Wide Field ModuleThis article is produced by iCare Finland for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Latest:
Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresisNonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Latest:
IOL designed for AMD offers hope for patientsExamining an intraocular implant that can sharpen vision for patients as disease progresses.
Latest:
The future of retina: New targets and more durable solutionsAmong the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.
Latest:
Creating the best care environment for patients with diabetic eye diseaseTunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.
Latest:
Why wait? The data show administering steroids to DME patients with good vision leads to long-term successA review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.
Latest:
Saving the world: Pharmaceutical innovation in nine monthsThe COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Latest:
Optimizing Care For Patients With Retinal DisordersKey takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Latest:
Patient Cases Demonstrating the Application of Treat and Extend Algorithm for Faricimab in DMEDr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.
Latest:
Expert insights: Ashkan Abbey, MD discusses 1-year results of DAVIO-2 trialAshkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.
Latest:
Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disordersThe use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
